Pelthos Therapeutics(PTHS.US)

Company Encyclopedia
View More
name
Pelthos Therapeutics
PTHS.US
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc.
1.896 T
PTHS.USMarket value -Rank by Market Cap -/-

Financial Score

02/01/2026 Update
D
BiotechnologyIndustry
Industry Ranking279/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-83.00%E
    • Profit Margin-318.41%E
    • Gross Margin66.77%A
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY-134.22%E
    • Total Assets YoY5808.39%A
    • Net Assets YoY4180.79%A
  • Cash ScoreD
    • Cash Flow Margin-31.41%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.12E
  • Debt ScoreC
    • Gearing Ratio53.93%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Alliance Global Partners Remains a Buy on Pelthos Therapeutics (PTHS)

    James Molloy from Alliance Global Partners has maintained a Buy rating on Pelthos Therapeutics (PTHS) with a price target of $75.00. The analyst consensus for PTHS is a Strong Buy, with an average price target of $59.80. Molloy focuses on the Healthcare sector and has an average return of -25.0% with a 23.91% success rate on his stock recommendations.

    Tip Ranks·
    US
    PTHS
    +12.77%
    Tip Ranks·
    US
    PTHS
    +12.77%

    Pelthos Therapeutics appoints Andrew Einhorn to its board, leveraging his 40+ years of expertise in finance and life sciences.

    An experienced executive with over 40 years of expertise in finance, capital markets, and life sciences has joined the team.

    Unusual Whales·
    US
    PTHS
    +12.77%
    Unusual Whales·
    US
    PTHS
    +12.77%

    Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn | PTHS Stock News

    Pelthos Therapeutics has appointed Andrew J. Einhorn to its Board of Directors, effective immediately. Einhorn, with four decades of finance and life sciences experience, will also serve on the Audit and Compensation Committees. His expertise is expected to aid Pelthos' growth as a commercially focused company. The board now has eight directors. Einhorn is a consultant at Danforth Advisors and has held CFO roles at several biotech firms. He is excited to contribute to Pelthos' mission as a new publicly traded company.

    StockTitan·
    US
    PTHS
    +12.77%
    StockTitan·
    US
    PTHS
    +12.77%

    Alliance Global Partners Sticks to Its Buy Rating for Pelthos Therapeutics (PTHS)

    Alliance Global Partners analyst James Molloy reiterated a Buy rating for Pelthos Therapeutics, setting a price target of $75.00. Molloy, who covers the Healthcare sector, has an average return of -25.0% and a 23.91% success rate. Pelthos Therapeutics has a Strong Buy consensus with a price target of $59.80.

    Tip Ranks·
    US
    PTHS
    +12.77%
    Tip Ranks·
    US
    PTHS
    +12.77%

    Pelthos Therapeutics Inc. held annual shareholder meeting

    Pelthos Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on December 17, 2025. All seven director nominees were elected, and stockholders approved the waiver on the share issuance limit for senior secured convertible notes. The appointment of CBIZ CPAs P.C. as the independent accounting firm for 2025 was ratified.

    Reuters·
    US
    PTHS
    +12.77%
    Reuters·
    US
    PTHS
    +12.77%
    © 2026 Longbridge｜Disclaimer